Topiramate as a Disease Altering Therapy for Cryptogenic Sensory Peripheral Neuropathy

NeuroNEXT and the National Institute of Neurological Disorders and Stroke (NINDS) are undergoing a double-blind, placebo clinical trial looking at the effectiveness of treating peripheral neuropathy with the FDA-approved drug, topiramate. This is a 96-week placebo-controlled trial of topiramate at a target dose of 100 mg daily (50 mg twice daily) as a potentially disease …

Topiramate as a Disease Altering Therapy for Cryptogenic Sensory Peripheral Neuropathy Read More »